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Abstract
Over the last 50 years there has been a move towards more aggressive therapy for well-differentiated thyroid cancer. In recent times, 
however, international guidelines have shown some trend back towards a more conservative approach to treating low-risk patients. This 
review explores how the state of the art in well-differentiated thyroid cancer research has evolved in tandem with improvements in risk-
stratification. A focus on the surgical approach to the primary thyroid tumour and the regional lymphatics in addition to the interplay 
between surgical decision making and the use of radioactive iodine are presented to allow the reader to determine whether they are now 
overtreating patients with well-differentiated thyroid cancer. (Endokrynol Pol 2016; 67 (1): 60–66)
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Streszczenie
W ciągu ostatnich 50 lat nastąpiła zmiana w leczeniu wysoko zróżnicowanego raka tarczycy na rzecz bardziej agresywnej terapii. Jed-
nakże, całkiem niedawno, międzynarodowe wytyczne wskazały trend w kierunku powrotu ku bardziej konserwatywnemu podejściu 
w leczeniu pacjentów niskiego ryzyka. W niniejszym artykule opisano jak najnowsze badania na temat wysoko zróżnicowanego raka 
tarczycy ewoluują równocześnie z ulepszeniami w stratyfikacji ryzyka. Podejście chirurgiczne do raka pierwotnego tarczycy oraz regio-
nalnych węzłów chłonnych przedstawiono wraz ze wzajemnymi zależnościami operacyjnego procesu decyzyjnego i wykorzystaniem 
radiojodu, aby umożliwić czytelnikowi ustalenie, czy zbyt intensywnie leczy pacjentów z wysoko zróżnicowanym rakiem tarczycy. 
(Endokrynol Pol 2016; 67 (1): 60–66)
Słowa kluczowe: rak tarczycy; rak brodawkowaty tarczycy; tyroidektomia; lobektomia tarczycy
Introduction
The approach to management of well-differentiated 
thyroid cancer (WDTC) has evolved over the past 
100 years. Advances in our understanding of the biology 
of disease have come during an evolution of therapeu-
tic opportunities for patients who are diagnosed with 
WDTC. Treatment approaches have become increas-
ingly standardised with the introduction of clinical 
guidelines, which have come to represent the consensus 
opinion on best practice within the field. 
Patients with WDTC generally have an excellent 
outcome [1, 2], but improvements in risk stratification 
have aided clinicians in identifying both those at high 
risk of recurrence or death and also those at low risk. 
Unfortunately, very little high-level evidence is 
available to clinicians managing patients with WDTC. 
The majority of papers are retrospective analyses of ei-
ther single institutional experiences or national database 
studies of data collected by clinical coders. Despite this, 
a large amount of often conflicting results are available, 
and the aim of this article is not to provide a one-size-
fits-all approach to managing patients with WDTC. 
Instead, the aim is to review the therapeutic options for 
patients presenting with WDTC, with a particular focus 
on those considered at low risk. In particular the paper 
will review the approach to surgery for the primary tu-
mour and regional lymph nodes. The review will cover 
the history of managing WDTC, the key studies that 
led us to the position we are in today, and the findings 
that are directing the changes we see in the most recent 
revisions of national clinical guidelines. 
The evolution of clinical thyroid outcomes 
research
For centuries clinicians have recognised that thyroid 
cancer can be an aggressive and rapidly fatal malig-
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nancy. These observations supported an aggressive ap-
proach to managing this condition with radical surgery 
for the primary thyroid and the regional lymphatics. 
However, in the early 20th century surgical pathologists 
were able identify those patients who would have poor 
outcomes from those who would do better based on 
light microscopy [3–6]. The recognition that poorly 
differentiated or anaplastic cancer was extremely ag-
gressive whereas differentiated thyroid cancers were 
much less likely to be fatal was a giant step in our un-
derstanding of the biology of this disease.
The relatively indolent nature of WDTC was 
a challenge to further outcomes research because, with 
so few recurrences and fatalities, large numbers of 
patients had to be followed for long periods in order 
to provide meaningful resources for analysis. The ex-
cellent outcomes reported by the Lahey clinic in 1976 
(5% mortality at 10 years) were supported by findings 
from other major groups and remain pertinent to this 
day [7, 8]. 
As more groups were able to analyse outcomes of 
large retrospective series, our understanding of both 
outcomes and factors associated with outcome im-
proved. The introduction of prognostic risk stratifica-
tion systems allowed clinicians both to identify those at 
high risk of poor outcome but also those patients who 
were low risk [9–12]. 
The introduction of large databases that collect 
patient and tumour details at a national level allowed 
groups to analyse outcomes in huge cohorts. This 
opportunity led to much interest in thyroid cancer 
outcomes research at a time when the incidence of this 
disease was rapidly rising. At a similar time, in order to 
provide larger cohorts of clinician-collected data, large 
institutions now collaborate in order to provide high-
quality retrospective data [13]. 
Prospective trials, however, remain lacking. Few 
have been performed, and most guideline recommen-
dations are based on low-level retrospective case series. 
Nonetheless, much has been learned over the past 100 
years, which can be used to inform treatment decisions 
for patients with WDTC.
Risk stratification in well-differentiated 
thyroid cancer
Although the majority of patients with WDTC do well, 
particularly in comparison with outcomes of other solid 
tumours, it is possible to predict accurately both the risk 
of recurrence and the risk of death. 
In the mid-20th century a number of groups rec-
ognised the importance of age in predicting outcome 
[9–12]. Young patients tended to have excellent out-
comes, with older patients at risk of disease specific 
death. Tumour factors, including size, the presence of 
extra thyroid extension, and the presence of distant 
metastases, were also associated with poor outcome. 
These patient and tumour factors were reflected in the 
numerous risk stratification systems designed to stratify 
patients by their risk of disease-specific death published 
in the mid to late 1900s (Table I). 
No particular approach has gained universal popular-
ity, and the existing AJCC/UICC staging system has been 
criticised and is likely to be significantly changed in the 
near future [14]. The Memorial Sloan Kettering Cancer 
Centre system (GAMES) considers patients as low or high 
risk based upon age. It recognises tumours as low risk if 
they are small and confined to the thyroid, and high risk 
if they are large or associated with distant metastases. 
Low-risk patients and low-risk tumours are considered as 
low-risk cases. High-risk patients with high-risk tumours 
are considered high-risk. Low-risk patients with high-risk 
tumours and high-risk patients with low-risk tumours 
represent an intermediate-risk group (Table II). 
More recently a system for predicting the risk of 
recurrence has been published by the American Thy-
roid Association (ATA) in the 2009 iteration of the ATA 
guidelines [15]. A potential advantage of this system is 
that, as most patients will not die of disease, recurrence 
is a more clinically meaningful outcome. However, a 
disadvantage of the system is that many of the features 
required to accurately use the system are only identified 
after initial surgery (Table III).
Although systems to predict outcome have been 
available for over 40 years, an understanding of risk 
stratification in WDTC is critical for clinicians. It not 
only allows for accurate prognostication, but also can 
aid in therapeutic decision-making. 
Primary thyroid surgery
As thyroid surgery became safer, techniques evolved 
and standardised to reject the nodulectomy pro-
cedure, which was associated with high levels of 
disease recurrence, in favour of total thyroidectomy 
and thyroid lobectomy as the procedures of choice 
in management of WDTC. With the publication of 
outcomes from the US Air Force database in 1977 
by Mazzaferri et al. came early evidence of guided 
management of the thyroid in the United States and 
across the world [16]. 
This paper, which analyses outcomes for 576 patients 
managed in the decades prior to 1976 in an air force 
medical setting, provided a cohort of patients treated 
in a fairly standardised manner and with a uniform 
approach to histological reporting. Many results were 
reported, but the ones that gained particular traction 
were those finding that outcomes were superior for 
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patients treated with total thyroidectomy versus less 
than total thyroidectomy, and for patients that received 
RAI versus those that did not. 
With the publication of this manuscript came the 
argument for an “aggressive” approach to patients 
with WDTC. Rates of total thyroidectomy rose in the 
USA, and a corresponding rise in the use of RAI was 
also reported [2]. 
Many papers scrutinising the impact of initial 
therapy followed, but an analysis of the National Cancer 
Database between 1985 and 1998 published by Bilmoria 
et al. confirmed the earlier findings of Mazzaferri [17]. 
This publication came at a time when the ATA were 
considering an update to their guideline document, 
which in 2009 recommended total thyroidectomy for 
all patients with tumours over 1 cm in size. 
However, not all groups agreed. Opponents of this 
standardised approach pointed out that the Mazzaferri 
paper lacked risk stratification. It was based on the 
outcomes of air force surgeons, who, while providing 
an excellent service to their patients in the 1930s and 
1940s, were likely to provide a very different surgical 
service to that delivered by trained endocrine surgeons 
of the late 20th and early 21st century. In addition, the 
approach to diagnostics and follow-up have changed 
significantly during the time that this patient group 
were managed. 
More contemporary data was criticised for lack-
ing basic important data such as the presence of extra 
thyroid extension and completeness of resection. In 
addition, outcomes data in terms of recurrence were 
lacking [18]. 
Table I. Comparison of risk stratification systems
Tabela I. Porównanie systemów stratyfikacji ryzyka
System AGES AM ES DAMES GAMES MACIS
Institution Mayo Clinic (1987) Lahey Clinie Karolinska Institute MSKCC Mayo Clinic (1993)
DNA ploidy Grade Metastasis (distant)
Age Age Age Age Age
Grade Metastases (distant) Metastases (distant) Metastases (distant) Completeness of 
resection
Factors Extra 
thyroid 
extension
Extra 
thyroid 
extension
Extra 
thyroid 
extension
Extra 
thyroid 
extension
Extra thyroid 
extension
Size Size Size Size Size
Table II. GAM ES Risk of CauseSpecifi:Mortalty Stratification (ETE = extrathyroid extension,Carcinoma)
Tabela II. GAM ES ryzyko i przyczyna działania: śmiertelność stratyfikacji (ETE = powiększenie tarczycy, rak)
Risk Level Patient Factor Tumor Factor
Low Risk Age < 45 years Papillary Ca M0 No ETE Size <4 cm
High Risk Age > 45 years Follicular Ca/ Hurthle Cel 
Ca
M1 ETE Size >4 cm
Low Risk Case Low Risk Patient Low Risk Tumor
lntermediate Risk Case Low Risk Patient High Risk Tumor
High  Risk Pat ent Low Risk Tumor
High Risk Case High  Risk Pat ent High  Risk Tumor
Table III. American Thyroid Association risk of recurrence stratification
Tabela III. Stratyfikacja ryzyka nawrotu według American Thyroid Association
Regional 
metastases
Distant  
metastases
Extra thyroid 
extension
Surgical 
resection
Aggressive 
pathology
RAI uptake outside 
thyroid bed
Low Risk Absent Absent Absent Complete Absent Absent
lntermediate Risk Present Absent Microscopic Complete Present Present
High Risk Present Macroscopic lncomplete
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The observation that less aggressive surgery is as-
sociated with excellent outcomes in properly selected 
patients is not new. In the Mayo clinic paper, which up-
dated their risk stratification system (MACIS) in 1987, no 
improvement in outcome was seen in low-risk patients 
[19]. Similar findings were reported by Memorial Sloan 
Kettering in a matched pair analysis [20]. Single institu-
tions would provide increasingly compelling evidence 
that more aggressive therapy was not associated with 
improved outcome [21–24]. These findings were sup-
ported by updated national database studies, which 
also concluded that a more aggressive approach could 
not be supported in low-risk groups [25]. 
Although there is little to choose in terms of onco-
logical outcome between total thyroidectomy and thy-
roid lobectomy, that is not to say patient outcomes are 
the same irrespective of the choice of therapy. Patients 
treated with total thyroidectomy are at greater risk of 
recurrent laryngeal nerve paralysis and hypocalcaemia 
[26]. Although injury rates are low in the hands of high-
volume surgeons, this is not true for surgeons with less 
experience. However, those patients who have a lobec-
tomy do require monitoring of the contralateral lobe, 
and around 10% of patients will require subsequent 
completion thyroidectomy if this approach is selected 
[23]. However, it is important to remember that this 
means that 90% of patients will not require completion 
thyroidectomy. 
Thyroid surgery is not performed in isolation. 
Not only does the procedure aim to rid the patient of 
disease, minimise the chance of recurrence, and avoid 
iatrogenic injury, but also prepares the patient for 
adjuvant therapy when indicated. Radioactive iodine 
therapy (RAI) is less effective unless a total thyroidec-
tomy has been performed. 
The role of RAI in the management of WDTC has 
been under much scrutiny in recent years. Although 
still supported for high-risk cases, its routine use in 
the lowest-risk cases is now discouraged. Risks of RAI 
include dry mouth and dysphagia with the potential to 
impact on patients’ quality of life [27, 28]. In addition, 
high doses have been associated with second primary 
malignancies [29], highlighting the need to only treat 
those most likely to benefit. 
The recent publication of two high-quality pro-
spective randomised controlled trials scrutinising the 
use of high dose RAI [30, 31] are to be followed by 
investigation of low-dose versus no RAI for low-risk 
WDTC [32]. It appears that the role of RAI is chang-
ing, and it is likely to be recommended in fewer 
patients in the low-risk group in the future. As such, 
the need for total thyroidectomy to facilitate RAI has 
a decreasing influence on the selection of surgical 
therapy for low-risk patients. 
Until recently, most clinical guidelines have sup-
ported total thyroidectomy for all patients with lesions 
> 1 cm. However, the ATA is now recommending an 
individualised approach for tumours between 1 and 
4 cm without evidence of disease outside the thyroid 
gland [33]. The British Thyroid Association has recom-
mended a similar approach [34]. 
High-risk patients require total thyroidectomy in 
order to rid them of disease, prepare them for adjuvant 
RAI, and to facilitate accurate thyroglobulin follow up. 
However, when selecting primary thyroid surgery in 
low-risk WDTC cases a balance must be achieved. In 
young patients and particularly professional voice us-
ers lobectomy may be preferred. For larger tumours 
and those demonstrating high-risk features, total thy-
roidectomy is likely to remains the standard of care. 
The treating clinician must also consider the chance of 
iatrogenic injury. Surgeons with low complication rates 
are likely to have a lower threshold for recommending 
total thyroidectomy than surgeons with higher compli-
cation rates. A balance must be struck on a case-by-case 
basis (Fig. 1). 
Surgery for regional lymphatics
Neck surgery can be considered therapeutic (when 
disease has been detected) or prophylactic (when no 
disease is identified pre-operatively). The role of thera-
peutic neck dissection is well defined and no longer 
controversial. The “berry-picking” procedure, where 
only clinically involved nodes are excised, has been 
abandoned in favour of a compartment-orientated 
approach. This involves dissection of levels II–V for 
involvement of the lateral neck and levels VI and VII 
for involvement of the central neck [35].
Prophylactic neck dissection, however, is far more con-
troversial. When performed, high rates of occult disease 
are identified. However, the impact of that disease is ques-
tionable because outcomes in low-risk patients (based on 
pre-operative features) are excellent. Lymphadenectomy 
is associated with morbidity, dependent on the region of 
dissection, and the perceived benefit must be balanced 
against the morbidity endured by the patient . 
Over the past century there has been an evolution 
in the approach to the neck. Early surgeons were ag-
gressive, dissecting electively in the central and lateral 
compartments. Recognition that there was little prog-
nostic implication led initially to a more conservative 
approach to the lateral neck, followed by questions 
being raised about the utility of routine prophylactic 
central neck dissection (pCND). At the same time, our 
ability to identify low-volume disease in the regional 
nodes improved with high-resolution ultrasound. As 
clinical intuition drove toward a more conservative 
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approach, radiological evidence was pushing toward 
a more aggressive approach, dissecting previously 
occult disease with a therapeutic approach (Fig. 2). 
In terms of the lateral neck, despite a significant 
percentage of patients harbouring occult disease, the 
high rates of surgical morbidity in addition to the low 
rate of progression to clinically meaningful disease 
have led most groups to abandon prophylactic lateral 
neck dissection. 
In contrast, the role of pCND is more controversial. 
This argument was brought to the fore when, in 2006, 
the ATA guideline was published with the wording 
that the prophylactic central neck dissection “should 
be considered” for papillary thyroid cancer [36]. This 
statement was interpreted by many as justification for 
pCND for all. 
Those who argue for a pCND cite the high rates of 
occult disease (as for the lateral neck) and highlight 
the fact that this additional knowledge allows patients 
to be more accurately risk stratified for the targeting 
of adjuvant RAI [37]. In addition, re-operative central 
neck surgery is associated with higher risks than an 
initial procedure. There has also been evidence to sug-
gest that post-operative thyroglobulin levels are lower 
and that weak evidence that recurrence rates may be 
lower as a result [38].
Those who argue against routine pCND point to 
evidence that the occult disease overlooked by this 
approach rarely manifests [39–41] and that this patient 
group is extremely low risk, so the concept of upstaging 
patients to be more aggressive in an era when the pen-
dulum is swinging away from RAI in low-risk patients 
seems counterintuitive. Although re-operative neck 
surgery is high risk, this must be balanced against the 
morbidity of routine pCND with thyroidectomy, which 
is more morbid than thyroid surgery alone [42–44]. In 
terms of oncological outcomes, no group has been able 
to show an improvement in recurrence rates, and it is 
well accepted that pCND does not impact on survival. 
To answer this question beyond doubt a prospective 
randomised trial would be required. However, when 
the ATA conducted a feasibility study they concluded 
that 5000 patients would have to be recruited and that 
the study design was not feasible [45]. A non-inferiority 
trial may be possible, but for the moment it seems 
unlikely that a definitive answer is going to be found. 
Few groups have published the outcome of patients 
managed without surgery. The Memorial Sloan Ketter-
ing Cancer Centre group studied almost 1800 patients 
with papillary thyroid cancer, who underwent total 
thyroidectomy without central neck dissection. In this 
study only 12 patients recurred in the central neck, and 
all were successfully salvaged. There were no deaths 
during follow-up [40]. This evidence, in support of oth-
Figure 1. Patient, disease and clinician factors which influence the approach to primary thyroid surgery
Rycina 1. Czynniki pacjenta, choroby i lekarza, wpływające na podejście do pierwszej operacji tarczycy
Figure 2. Factors which have resulted in the trend initially towards 
less then more neck surgery for well-differentiated thyroid cancer
Rycina 2. Czynniki wpływające na mniej lub bardziej inwazyjny 
zakres operacji w obrębie szyi z powodu wysoko zróżnicowanego 
raka tarczycy
Aggressiveness of Primary Thyroid Surgery
Young age, professional voice user, 
comfortable obseving contralateral 
lobe
Patient Factors Older age, less reliable for follow up
Small volume primery, uninodular, 
no cvidence of extra thyroid extension, 
nodal or distant metastases, 
non aggressive histological features
Disease Factors Large volume primary, multinodular, 
evidence of extra thyroid extension 
nodal or distant metastases, 
non aggressive histological features
High complication rates Clinician Factors Low complication rates
Thyroid Lobectomy Total Thyroidectomy
Increased rates 
of therapeutic 
neck dissection
More Neck Surgery
No prognostic implication
Elective lateral ND 
abandoned
Role of pCND in question
Less Neck Surgery
Increasing 
Resolution 
of Ultrasound
Previously Occult 
Metastatic 
Disease Identified
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ers’ findings, suggests that observation of the central 
neck is safe, does not prevent later salvage in those 
that recur, and protects the vast majority (> 98% in this 
study) from the risks of central neck surgery. Another 
consideration is that novel surgical approaches often 
require high levels of surgical experience and resources. 
In contrast, not performing a central neck dissection can 
be practiced by any clinician equally effectively. 
An improved understanding of the biology of the 
undissected central neck has led to a softening of the 
language of the ATA. The initial statement that pCND 
“should be considered” was changed to “may be con-
sidered” in 2009, and in the 2015 guideline it reads 
“management without pCND may be appropriate”. 
While not advocating an abandoning of pCND, there 
does appear to be a gradual shift away from a single 
approach for all patients. 
Challenges for the Future
There remain challenges in translating a less aggressive 
approach to the real word for many clinicians. Those 
patients who present with a malignancy in the pres-
ence of multinodular goitre are currently consigned to 
total thyroidectomy. Advances in imaging may allow 
for the risk of malignancy within the rest of the gland 
to be accurately quantified to allow such patients to be 
managed without total thyroidectomy. This is particu-
larly an issue as the resolution of ultrasound increases 
and ever smaller volume nodular disease is identified. 
It is also important to consider the role of no 
treatment in the lowest-risk patients. A number of 
Japanese groups have demonstrated a few patients 
with micro carcinoma progress during a period of ac-
tive observation [46–49]. Current studies include only 
sub-centimetre lesions. However, the 10-mm cut-off is 
arbitrary and could be extended, particularly given the 
recent finding that adverse events during follow-up 
are actually higher for such low-risk patients who opt 
for surgery versus observation [49]. It is possible that 
as molecular analysis of biopsy samples improves, the 
lowest-risk tumour biology will be better characterised 
allowing an increasing number of patients who can 
avoid surgery altogether. 
Conclusion
As our understanding of well-differentiated thyroid 
cancer has evolved, our ability to predict the risk of 
recurrence and death from disease has improved. This 
ability to accurately predict the risk status of an indi-
vidual allows clinicians to identify those patients at the 
highest risk of poor outcome and focus resources on that 
group. In addition, it provides the opportunity to con-
sider the lowest-risk group for less aggressive therapy. 
This approach will not suit all patients, but by being 
able to balance the risks of surgery against the likely 
clinical outcomes, disease management teams will be 
better able to serve their patients. The ability to identify 
those patients in whom the risks of prophylactic central 
neck dissection may outweigh the benefits, and by 
understanding the changing role of RAI in the manage-
ment of WDTC in tandem with the likely outcome of 
an observed contralateral thyroid lobe, clinicians will 
be able to individualise therapy without compromising 
oncological outcomes. 
Only with an insight in to these factors will you be 
able to determine whether you are overtreating your 
patients with well-differentiated thyroid cancer. 
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